"The analysis of clinical trials in people with mild cognitive impairment or mild dementia found that the effects of anti-amyloid drugs on cognition and dementia severity over 18 months were trivial, with improvements in functional ability small at best."
"It's not surprising that if you pool results from effective and ineffective treatments you end up with a small or absent average treatment effect, said Charles Marshall, professor of clinical neurology at Queen Mary, University of London."
"Despite the drugs slowing the disease by four to six months, the cost to the NHS was not justified."
"The Cochrane review analysed 17 clinical trials that typically lasted 18 months, involving more than 20,000 people and assessing seven anti-amyloid drugs."
An extensive review of clinical trials indicates that anti-amyloid drugs for Alzheimer's disease have minimal impact on cognition and dementia severity. The analysis covered 17 trials involving over 20,000 participants with mild cognitive impairment or mild dementia, revealing only small improvements in functional ability. Critics argue that combining results from both effective and ineffective treatments led to misleading conclusions. Despite initial optimism and regulatory approvals for drugs like lecanemab and donanemab, the National Institute for Health and Care Excellence in the UK deemed their cost unjustifiable for public health services.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]